US FDA clears RapidAI’s software for large vessel occlusions detection

14 August 2020 (Last Updated August 14th, 2020 12:41)

The US Food and Drug Administration (FDA) has cleared RapidAI’s Rapid LVO software for the detection of suspected large vessel occlusions (LVOs).

The US Food and Drug Administration (FDA) has cleared RapidAI’s Rapid LVO software for the detection of suspected large vessel occlusions (LVOs).

Rapid LVO is designed to assist physicians in faster triage or transfer decision-making. To identify suspected large vessel occlusions, the application uses a vessel tracker and assessment of brain regions that have reduced blood vessel density.

The results and source files will be delivered to team members through PACS, email and the Rapid Mobile App. In addition, when a suspected LVO is detected, stroke team members will be immediately notified.

It works in as little as three minutes with a sensitivity of 97% and a specificity of 96%.

RapidAI co-founder Dr Greg Albers said: “LVOs are the most disabling and deadly ischemic strokes.

“The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care.”

RapidAI specialises in advanced imaging for stroke. The company provides stroke imaging software for patient care, research and clinical trials globally.

Developed by the company, the solution includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, Rapid MRI and Rapid LVO. It is said to be the only clinically validated platform available for advanced cerebrovascular imaging.

RapidAI also offers SurgicalPreview, a Cloud-based computational platform designed for comprehensive cerebral aneurysm management.

Using the patient’s MRI scan, the platform generates a 3D model of the vasculature and provides clinically relevant information for aneurysm treatment.